On the public citation graph

Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma

0 signed · 144 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/bjs.7455openalex-snapshot
Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer
inferredcites →https://doi.org/10.1002/ijc.31312openalex-snapshot
Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta‐analysis
inferredcites →https://doi.org/10.1007/s10388-016-0551-7openalex-snapshot
Japanese Classification of Esophageal Cancer, 11th Edition: part I
inferredcites →https://doi.org/10.1007/s10388-016-0556-2openalex-snapshot
Japanese Classification of Esophageal Cancer, 11th Edition: part II and III
inferredcites →https://doi.org/10.1016/j.bpg.2018.11.012openalex-snapshot
The management of mid & proximal oesophageal squamous cell carcinoma
inferredcites →https://doi.org/10.1016/j.ijrobp.2019.12.038openalex-snapshot
Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using 18F-FDG PET/CT and DW-MRI: A Prospective Multicenter Study
inferredcites →https://doi.org/10.1016/j.ijsu.2018.09.013openalex-snapshot
Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis
inferredcites →https://doi.org/10.1016/j.jtho.2017.03.024openalex-snapshot
The Impact of Postoperative Conformal Radiotherapy after Radical Surgery on Survival and Recurrence in Pathologic T3N0M0 Esophageal Carcinoma: A Propensity Score-Matched Analysis
inferredcites →https://doi.org/10.1016/j.radonc.2015.07.020openalex-snapshot
Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case–control study
inferredcites →https://doi.org/10.1016/s0022-5223(97)70147-8openalex-snapshot
Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: A prospective randomized trial
inferredcites →https://doi.org/10.1016/s0140-6736(12)60643-6openalex-snapshot
Oesophageal carcinoma
inferredcites →https://doi.org/10.1016/s1470-2045(11)70142-5openalex-snapshot
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis
inferredcites →https://doi.org/10.1016/s1470-2045(15)00040-6openalex-snapshot
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30531-9openalex-snapshot
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a…
inferredcites →https://doi.org/10.1016/s1470-2045(20)30110-8openalex-snapshot
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
inferredcites →https://doi.org/10.1038/srep38804openalex-snapshot
Metastatic lymph node ratio demonstrates better prognostic stratification than pN staging in patients with esophageal squamous cell carcinoma after esophagectomy
inferredcites →https://doi.org/10.1056/nejmoa055531openalex-snapshot
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
inferredcites →https://doi.org/10.1056/nejmoa1112088openalex-snapshot
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
inferredcites →https://doi.org/10.1093/annonc/mdw010openalex-snapshot
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction
inferredcites →https://doi.org/10.1093/dote/doz078openalex-snapshot
Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study
inferredcites →https://doi.org/10.1093/dote/doz080openalex-snapshot
Short- and mid-term outcomes of robotic versus thoraco-laparoscopic McKeown esophagectomy for squamous cell esophageal cancer: a propensity score-matched study
inferredcites →https://doi.org/10.1093/ejcts/ezw246openalex-snapshot
Factors associated with survival in patients with oesophageal cancer who achieve pathological complete response after chemoradiotherapy: a nationwide population-based study
inferredcites →https://doi.org/10.1093/ejcts/ezw315openalex-snapshot
Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer
inferredcites →https://doi.org/10.1093/icvts/ivaa038openalex-snapshot
Effectiveness and safety of minimally invasive Ivor Lewis and McKeown oesophagectomy in Chinese patients with stage IA–IIIB oesophageal squamous cell cancer: a multicentre, non-interventional and observational study
inferredcites →https://doi.org/10.1093/jjco/hyt061openalex-snapshot
Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study)
inferredcites →https://doi.org/10.1093/jjco/hyv119openalex-snapshot
Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer
inferredcites →https://doi.org/10.1097/00000658-199409000-00012openalex-snapshot
Radical Lymph Node Dissection for Cancer of the Thoracic Esophagus
inferredcites →https://doi.org/10.1097/01.sla.0000086545.45918.eeopenalex-snapshot
Improvement in Treatment Results and Long-Term Survival of Patients With Esophageal Cancer
inferredcites →https://doi.org/10.1097/sla.0000000000003727openalex-snapshot
Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus
inferredcites →https://doi.org/10.1097/sla.0b013e3181949e9fopenalex-snapshot
Pretreatment T3-4 Stage is an Adverse Prognostic Factor in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response Following Preoperative Chemoradiotherapy
inferredcites →https://doi.org/10.1097/sla.0b013e3181fb8ddeopenalex-snapshot
A Multicenter Study of Survival After Neoadjuvant Radiotherapy/Chemotherapy and Esophagectomy for ypT0N0M0R0 Esophageal Cancer
inferredcites →https://doi.org/10.1111/1759-7714.12299openalex-snapshot
Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta‐analysis
inferredcites →https://doi.org/10.1111/1759-7714.12590openalex-snapshot
Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
inferredcites →https://doi.org/10.1111/his.13811openalex-snapshot
Neoadjuvant chemoradiation for patients with advanced oesophageal cancer – which response grading system best impacts prognostic discrimination?
inferredcites →https://doi.org/10.1159/000357189openalex-snapshot
The Current Evidence in Support of Multimodal Treatment of Locally Advanced, Potentially Resectable Esophageal Cancer
inferredcites →https://doi.org/10.1159/000375391openalex-snapshot
Postoperative Intensity-Modulated Radiotherapy Improved Survival in Lymph Node-Positive or Stage III Thoracic Esophageal Squamous Cell Carcinoma
inferredcites →https://doi.org/10.1186/s12885-017-3446-7openalex-snapshot
CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0) (NCT03001596)
inferredcites →https://doi.org/10.1186/s12885-018-4892-6openalex-snapshot
Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study
inferredcites →https://doi.org/10.1186/s12957-020-02023-2openalex-snapshot
Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus
inferredcites →https://doi.org/10.1200/jco.2003.12.095openalex-snapshot
Surgery Plus Chemotherapy Compared With Surgery Alone for Localized Squamous Cell Carcinoma of the Thoracic Esophagus: A Japan Clinical Oncology Group Study—JCOG9204
inferredcites →https://doi.org/10.1200/jco.2007.12.9593openalex-snapshot
Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781
inferredcites →https://doi.org/10.1200/jco.2010.33.0597openalex-snapshot
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
inferredcites →https://doi.org/10.1200/jco.2013.53.6532openalex-snapshot
Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901
inferredcites →https://doi.org/10.1200/jco.2018.79.1483openalex-snapshot
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
inferredcites →https://doi.org/10.1245/s10434-009-0862-1openalex-snapshot
Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer
inferredcites →https://doi.org/10.1245/s10434-011-2049-9openalex-snapshot
A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)
inferredcites →https://doi.org/10.1245/s10434-017-5808-4openalex-snapshot
Comparison of Short-Term Outcomes Between Open and Minimally Invasive Esophagectomy for Esophageal Cancer Using a Nationwide Database in Japan
inferredcites →https://doi.org/10.1378/chest.93.5.1054openalex-snapshot
Preoperative Radioactive Therapy for Esophageal Carcinoma
inferredcites →https://doi.org/10.21037/jtd.2017.01.44openalex-snapshot
A phase III, multicenter randomized controlled trial of neo-adjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma
inferredcites →https://doi.org/10.21037/jtd.2018.03.175openalex-snapshot
Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition)
inferredcites →https://doi.org/10.21037/jtd.2018.12.07openalex-snapshot
Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma
inferredcites →https://doi.org/10.21147/j.issn.1000-9604.2019.02.01openalex-snapshot
Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version)
inferredcites →https://doi.org/10.2217/fon-2019-0024openalex-snapshot
Comparison of Neoadjuvant Chemoradiotherapy and Neoadjuvant Chemotherapy for Esophageal Cancer: A Meta-Analysis
inferredcites →https://doi.org/10.2217/fon-2020-0189openalex-snapshot
Feasibility Study of Nivolumab as Neoadjuvant Chemotherapy for Locally Esophageal Carcinoma: FRONTiER (JCOG1804E)
inferredcites →https://doi.org/10.3322/caac.21492openalex-snapshot
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
inferredcites →https://doi.org/10.3748/wjg.v20.i47.18022openalex-snapshot
Three-fieldvstwo-field lymph node dissection for esophageal cancer: A meta-analysis
inferredcites →https://doi.org/10.3748/wjg.v21.i28.8644openalex-snapshot
Aggressive surgical resection does not improve survival in operable esophageal squamous cell carcinoma with N2-3 status
inferredcites →https://doi.org/10.6004/jnccn.2019.0033openalex-snapshot
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
inferredcites →https://doi.org/10.7150/jca.17048openalex-snapshot
TNM Staging Matched-pair Comparison of Surgery After Neoadjuvant Chemoradiotherapy, Surgery Alone and Definitive Chemoradiotherapy for Thoracic Esophageal Squamous Cell Carcinoma

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.5366120openalex-extracted
inferred← citeshttps://doi.org/10.1002/adhm.202303623openalex-snapshot
Tackling Esophageal Squamous Cell Carcinoma with ITFn‐Pt(IV): A Novel Fusion of PD‐L1 Blockade, Chemotherapy, and T‐cell Activation
inferred← citeshttps://doi.org/10.1007/s00262-022-03354-7openalex-snapshot
Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment
inferred← citeshttps://doi.org/10.1007/s11912-021-01153-4openalex-snapshot
Update on Management of Squamous Cell Esophageal Cancer
inferred← citeshttps://doi.org/10.1007/s12013-025-01802-6openalex-snapshot
A Risk Prognostic Signature Basing on Cuproptosis-related Ferroptosis and Immune Genes for Esophageal Squamous Cell Carcinoma Patients
inferred← citeshttps://doi.org/10.1007/s12029-023-00980-xopenalex-snapshot
Non-endoscopic Screening for Esophageal Squamous Cell Carcinoma: Recent Advances
inferred← citeshttps://doi.org/10.1007/s12094-023-03133-5openalex-snapshot
Phosphorylation of AKT by lysyl oxidase-like 2 activates the PI3K/AKT signaling pathway to promote proliferation, invasion and metastasis in esophageal squamous carcinoma
inferred← citeshttps://doi.org/10.1007/s12672-026-05419-wopenalex-snapshot
Context-dependent roles of lncRNA JPX in human cancers
inferred← citeshttps://doi.org/10.1016/j.ajpath.2021.12.002openalex-snapshot
S100A8/A9 Induced by Interaction with Macrophages in Esophageal Squamous Cell Carcinoma Promotes the Migration and Invasion of Cancer Cells via Akt and p38 MAPK Pathways
inferred← citeshttps://doi.org/10.1016/j.athoracsur.2022.07.052openalex-snapshot
Lymphovascular and Perineural Invasion After Neoadjuvant Therapy in Esophageal Squamous Carcinoma
inferred← citeshttps://doi.org/10.1016/j.canlet.2021.09.035openalex-snapshot
STAT3β disrupted mitochondrial electron transport chain enhances chemosensitivity by inducing pyroptosis in esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.chom.2026.02.019openalex-snapshot
Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2024.104362openalex-snapshot
Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors
inferred← citeshttps://doi.org/10.1016/j.ejphar.2022.175317openalex-snapshot
lncRNA BBOX1-AS1 silencing inhibits esophageal squamous cell cancer progression by promoting ferroptosis via miR-513a-3p/SLC7A11 axis
inferred← citeshttps://doi.org/10.1016/j.ijsu.2022.106767openalex-snapshot
Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.lanwpc.2023.100841openalex-snapshot
Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1016/j.tranon.2023.101775openalex-snapshot
The level of macrophage migration inhibitory factor is negatively correlated with the efficacy of PD-1 blockade immunotherapy combined with chemotherapy as a neoadjuvant therapy for esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.yexcr.2022.113130openalex-snapshot
LncRNA GATA2-AS1 suppresses esophageal squamous cell carcinoma progression via the mir-940/PTPN12 axis
inferred← citeshttps://doi.org/10.1038/s41416-023-02547-wopenalex-snapshot
Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test
inferred← citeshttps://doi.org/10.1038/s41419-024-07240-1openalex-snapshot
GPR37-enhanced ubiquitination of ATP1A1 inhibits tumor progression and radiation resistance in esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1038/s41420-023-01689-3openalex-snapshot
IDO1 facilitates esophageal carcinoma progression by driving the direct binding of NF-κB and CXCL10
inferred← citeshttps://doi.org/10.1038/s41598-023-41495-6openalex-snapshot
Identification of m5C-related lncRNAs signature to predict prognosis and therapeutic responses in esophageal squamous cell carcinoma patients
inferred← citeshttps://doi.org/10.1080/14737140.2024.2341737openalex-snapshot
Role of non-coding RNAs mediated pyroptosis on cancer therapy: a review
inferred← citeshttps://doi.org/10.1089/cbr.2021.0086openalex-snapshot
Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.1093/bjs/znac314openalex-snapshot
Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison
inferred← citeshttps://doi.org/10.1093/dote/doad073openalex-snapshot
Clinical study of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1093/jjco/hyad051openalex-snapshot
Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer
inferred← citeshttps://doi.org/10.1093/oncolo/oyab011openalex-snapshot
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.1097/as9.0000000000000385openalex-snapshot
Neoadjuvant Chemoradiotherapy Upregulates the Immunogenicity of Cold to Hot Tumors in Esophageal Cancer Patients
inferred← citeshttps://doi.org/10.1097/cej.0000000000000788openalex-snapshot
Cytoplasmic poly(A)-binding protein 1 as a biomarker to assist early diagnosis and prognosis of esophageal squamous cell carcinoma in endoscopic biopsy fragments
inferred← citeshttps://doi.org/10.1097/md.0000000000050798openalex-snapshot
Association between postoperative nasogastric tube retention duration and total postoperative opioid consumption in patients undergoing minimally invasive esophagectomy
inferred← citeshttps://doi.org/10.1099/jmm.0.001723openalex-snapshot
Gut microbiota associated with the mitigation effect of synbiotics on adverse events of neoadjuvant chemotherapy in patients with esophageal cancer: A retrospective exploratory study
inferred← citeshttps://doi.org/10.1111/1759-7714.14130openalex-snapshot
Trimodality therapy for esophageal cancer: The role of surgical and radiation treatment parameters in the development of anastomotic complications
inferred← citeshttps://doi.org/10.1111/1759-7714.15391openalex-snapshot
Changes in the recent three decades and survey on the current status of surgical treatment for esophageal cancer in China
inferred← citeshttps://doi.org/10.1136/jitc-2021-003497openalex-snapshot
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1155/2024/5542947openalex-snapshot
The Neoadjuvant Administration of PD‐1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous‐Cell Carcinoma
inferred← citeshttps://doi.org/10.1186/s12885-022-09423-5openalex-snapshot
Prognostic variables for conditional survival in patients with esophageal squamous cell carcinoma who underwent minimally invasive surgery
inferred← citeshttps://doi.org/10.1186/s12885-024-11886-7openalex-snapshot
Increased resected lymph node stations improved survival of esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1186/s12885-024-12510-4openalex-snapshot
IKBIP promotes tumor development via the akt signaling pathway in esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1186/s12893-023-02023-5openalex-snapshot
Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
inferred← citeshttps://doi.org/10.1186/s12957-022-02732-wopenalex-snapshot
A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
inferred← citeshttps://doi.org/10.1186/s12967-022-03252-7openalex-snapshot
Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1186/s13019-024-02500-9openalex-snapshot
Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III–IVA esophageal squamous cell carcinoma post-surgery
inferred← citeshttps://doi.org/10.1371/journal.pone.0291531openalex-snapshot
The anti-tumor activity of tangeretin in esophageal squamous cell carcinoma by inhibiting GLI2-mediated transcription of GPNMB
inferred← citeshttps://doi.org/10.14218/jctp.2024.00007openalex-snapshot
A Review and Update on Therapy of Gastrointestinal Tract Tumors: From the Bench to Clinical Practice
inferred← citeshttps://doi.org/10.20517/2394-4722.2025.156openalex-snapshot
The predictive role of hematologic indicators in locally advanced esophageal squamous cell carcinoma patients receiving neoadjuvant chemoimmunotherapy
inferred← citeshttps://doi.org/10.21037/jgo-21-610openalex-snapshot
Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.21037/jtd-22-948openalex-snapshot
Development and validation of a prognostic model related to pyroptosis-related genes for esophageal squamous cell carcinoma using bioinformatics analysis
inferred← citeshttps://doi.org/10.21037/tcr-21-2404openalex-snapshot
Effects of long-term exposure to sevoflurane on the proliferation, migration, invasion, and cisplatin sensitivity of esophageal cancer
inferred← citeshttps://doi.org/10.21037/tcr-24-198openalex-snapshot
Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for resectable esophageal cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1085112/v1openalex-snapshot
Screening and Evaluating Novel Autoantibodies Based on Proteomic Chips in Diagnosis of Esophageal Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.21203/rs.3.rs-3538085/v1openalex-snapshot
Neoadjuvant sintilimab and chemotherapy for resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II study
inferred← citeshttps://doi.org/10.21203/rs.3.rs-5797124/v1openalex-snapshot
Comparative Analysis of Clinical Outcomes Between Neoadjuvant Chemoimmunotherapy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Retrospective Study
inferred← citeshttps://doi.org/10.2147/cmar.s295646openalex-snapshot
Change in Maximal Esophageal Wall Thickness Provides Prediction of Survival and Recurrence in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy and Surgery
inferred← citeshttps://doi.org/10.2147/jir.s463163openalex-snapshot
The Systemic Immune-Inflammation Index as an Independent Predictor of Survival in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Radiotherapy
inferred← citeshttps://doi.org/10.26717/bjstr.2023.52.008216openalex-snapshot
"Assessment of Tumor Size Changes After Neoadjuvant Chemotherapy in Locally Advanced Esophageal Cancer: An Original Article"
inferred← citeshttps://doi.org/10.32604/or.2025.060151openalex-snapshot
Gallic acid suppresses esophageal squamous cell carcinoma progression and enhances cisplatin chemosensitivity through IL-6/STAT3/Notch pathway
inferred← citeshttps://doi.org/10.3389/fendo.2021.651438openalex-snapshot
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1066527openalex-snapshot
Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1412693openalex-snapshot
Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1660897openalex-snapshot
An interpretable machine learning model using multimodal pretreatment features predicts pathological complete response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.3389/fonc.2022.977935openalex-snapshot
Global research trend of esophageal squamous cell carcinoma from 2012 to 2022: a bibliometric analysis
inferred← citeshttps://doi.org/10.3389/fonc.2023.1257266openalex-snapshot
Role of cancer-associated fibroblasts in the progression, therapeutic resistance and targeted therapy of oesophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.3389/fonc.2024.1498675openalex-snapshot
Efficacy and prognosis biomarker of locally advanced ESCC patients treated with neoadjuvant chemotherapy and anti-PD-1 immunotherapy
inferred← citeshttps://doi.org/10.3389/fonc.2025.1508477openalex-snapshot
Prognostic factors in locally advanced oesophageal squamous cell carcinoma: a clinical and radiomic analysis of neoadjuvant immunochemotherapy before surgery
inferred← citeshttps://doi.org/10.3389/fonc.2025.1511691openalex-snapshot
CT-based radiomics for prediction of response to neoadjuvant immunochemotherapy in patients with esophageal carcinoma
inferred← citeshttps://doi.org/10.3389/fphar.2022.873166openalex-snapshot
Celastrol Inhibited Human Esophageal Cancer by Activating DR5-Dependent Extrinsic and Noxa/Bim-Dependent Intrinsic Apoptosis
inferred← citeshttps://doi.org/10.3389/fsurg.2022.1091601openalex-snapshot
Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer
inferred← citeshttps://doi.org/10.3390/bioengineering12080813openalex-snapshot
CT-Based Habitat Radiomics Combining Multi-Instance Learning for Early Prediction of Post-Neoadjuvant Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.3390/cancers18010155openalex-snapshot
Three-Year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Neoadjuvant Chemoradiotherapy in Resectable Esophageal Cancer: A Multicenter Retrospective Study
inferred← citeshttps://doi.org/10.3390/ijms24065586openalex-snapshot
RIG-I Promotes Tumorigenesis and Confers Radioresistance of Esophageal Squamous Cell Carcinoma by Regulating DUSP6
inferred← citeshttps://doi.org/10.3724/abbs.2023154openalex-snapshot
LincRNA-P21 knockdown facilitates esophageal squamous cell carcinoma cell progression by upregulating cadherin 5 via YTH domain containing 1
inferred← citeshttps://doi.org/10.3748/wjg.v29.i34.5020openalex-snapshot
Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future
inferred← citeshttps://doi.org/10.3748/wjg.v31.i4.101749openalex-snapshot
Nomogram based on a novel nutritional immune-inflammatory status score to predict postoperative outcomes in esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.3748/wjg.v31.i45.112287openalex-snapshot
Organ preservation in esophageal cancer treatment, is it time now?
inferred← citeshttps://doi.org/10.3892/ijo.2023.5530openalex-snapshot
Targeting the mitochondrial calcium uniporter inhibits cancer progression and alleviates cisplatin resistance in esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.3892/ol.2022.13654openalex-snapshot
Identification and validation of DPY30 as a prognostic biomarker and tumor immune microenvironment infiltration characterization in esophageal cancer
inferred← citeshttps://doi.org/10.4103/jmas.jmas_65_23openalex-snapshot
The efficacy and feasibility of neoadjuvant immunotherapy plus chemotherapy followed by McKeown minimally invasive oesophagectomy for locally advanced oesophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.4251/wjgo.v16.i1.1openalex-snapshot
Present situation and prospect of immunotherapy for unresectable locally advanced esophageal cancer during peri-radiotherapy
inferred← citeshttps://doi.org/10.6084/m9.figshare.20652805openalex-snapshot
Additional file 1 of A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.20652811openalex-snapshot
Additional file 2 of A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.25150554openalex-snapshot
Additional file 1 of Increased resected lymph node stations improved survival of esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.6084/m9.figshare.26094420openalex-snapshot
Additional file 1 of IKBIP promotes tumor development via the akt signaling pathway in esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.62347/ktpz5454openalex-snapshot
Neoadjuvant chemotherapy plus immunotherapy for locally advanced esophageal cancer
inferred← citeshttps://doi.org/10.7759/cureus.22286openalex-snapshot
Medical Oncology or Surgical Oncology: Which Branch Should Be Started in Esophageal Cancer Diagnostic Evaluation?
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.